Copy to clipboard 
Anika Therapeutics has appointed Stephen (Steve) Griffin, current Executive Vice President, Chief Financial Officer and Chief Operating Officer, as President and Chief Executive Officer and a member of the Board of Directors, effective February 1, 2026. Mr. Griffin will succeed Cheryl R. Blanchard, Ph.D., who will become Executive Chair of the Board of Directors.
Mr. Griffin, who has served as Anika’s CFO since 2024 and COO since April 2025, brings a track record of successful strategic transformation and operational excellence to his next role as CEO. At Anika, he has led the divestiture of assets such as Arthrosurface and Parcus Medical as the company focused its strategy around hyaluronic acid, and strengthened operations through reinvestment and process improvements.
“We are thrilled to announce Steve’s appointment as our next CEO. Since joining the company in 2024, Steve has been an exceptional, highly capable leader who has played an integral role advancing key strategic priorities, including accelerating profitability and positioning Anika to capture the significant value in our pipeline,” said Dr. Blanchard. “It has been a tremendous privilege to serve as Anika’s CEO for six years. I am proud of what our team has accomplished to restore active living for people globally as we refocused our strategy around Anika’s hyaluronic acid portfolio in both OA pain management and regenerative solutions. This includes launching the Integrity Implant System to treat tendon repairs, progressing our compelling clinical pipeline, and driving double-digit growth in our commercial channel.”
Further, the company reaffirmed its fiscal 2025 guidance, which was previously reaffirmed on November 5, 2025, in conjunction with its third quarter 2025 financial results. Mr. Griffin will need to bring stability to Anika’s up-and-down sales, especially in its largest segment, orthobiologics, which has declined in two consecutive years.
Mr. Griffin said, “We have the right building blocks in place, and now is the time to execute with urgency and purpose. Through Cheryl’s leadership, the company is well positioned for its next chapter, and I look forward to partnering with her as Executive Chair to deliver on the profitable growth opportunities ahead for Anika.”
Source: Anika
Anika Therapeutics has appointed Stephen (Steve) Griffin, current Executive Vice President, Chief Financial Officer and Chief Operating Officer, as President and Chief Executive Officer and a member of the Board of Directors, effective February 1, 2026. Mr. Griffin will succeed Cheryl R. Blanchard, Ph.D., who will become Executive Chair of the...
Anika Therapeutics has appointed Stephen (Steve) Griffin, current Executive Vice President, Chief Financial Officer and Chief Operating Officer, as President and Chief Executive Officer and a member of the Board of Directors, effective February 1, 2026. Mr. Griffin will succeed Cheryl R. Blanchard, Ph.D., who will become Executive Chair of the Board of Directors.
Mr. Griffin, who has served as Anika’s CFO since 2024 and COO since April 2025, brings a track record of successful strategic transformation and operational excellence to his next role as CEO. At Anika, he has led the divestiture of assets such as Arthrosurface and Parcus Medical as the company focused its strategy around hyaluronic acid, and strengthened operations through reinvestment and process improvements.
“We are thrilled to announce Steve’s appointment as our next CEO. Since joining the company in 2024, Steve has been an exceptional, highly capable leader who has played an integral role advancing key strategic priorities, including accelerating profitability and positioning Anika to capture the significant value in our pipeline,” said Dr. Blanchard. “It has been a tremendous privilege to serve as Anika’s CEO for six years. I am proud of what our team has accomplished to restore active living for people globally as we refocused our strategy around Anika’s hyaluronic acid portfolio in both OA pain management and regenerative solutions. This includes launching the Integrity Implant System to treat tendon repairs, progressing our compelling clinical pipeline, and driving double-digit growth in our commercial channel.”
Further, the company reaffirmed its fiscal 2025 guidance, which was previously reaffirmed on November 5, 2025, in conjunction with its third quarter 2025 financial results. Mr. Griffin will need to bring stability to Anika’s up-and-down sales, especially in its largest segment, orthobiologics, which has declined in two consecutive years.
Mr. Griffin said, “We have the right building blocks in place, and now is the time to execute with urgency and purpose. Through Cheryl’s leadership, the company is well positioned for its next chapter, and I look forward to partnering with her as Executive Chair to deliver on the profitable growth opportunities ahead for Anika.”
Source: Anika
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
